MedTrace Logo

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)

NCT00094770 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1172

Last updated 2016-08-26

Study results available
· View outcomes & findings →

Summary

The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

sitagliptin (MK0431)

Sitagliptin 100 mg oral tablets of sitagliptin once daily.

DRUG

Comparator: glipizide

Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2006-05-31
Completion
2007-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00094770 on ClinicalTrials.gov